Navigation Links
Long-term apremilast demonstrates continued efficacy in patients with psoriatic arthritis
Date:6/12/2013

Madrid, Spain, 12 June 2013: New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks. For patients who completed 52 weeks of the study, up to 65% achieved ACR20* response rates. Also, apremilast continued to be well tolerated with an acceptable longer-term safety profile.

Apremilast is a novel, oral small-molecule inhibitor of phosphodiesterase 4 (PDE4). It works as an anti-inflammatory drug by modulating a network of pro- and anti-inflammatory mediators inside cells.

PsA is a chronic inflammatory arthritis associated with psoriasis which significantly impacts health-related quality of life in patients, and increases risk of co-morbid cardiovascular and gastrointestinal disease.2 Psoriasis occurs in 2-3% of the population, with PsA occurring in up to 30% of those of cases.3

"Over the course of their disease patients with psoriatic arthritis may take a variety of treatment regimens over extended periods of time. Durability of response is therefore important. This relatively large study suggests that apremilast has sustained efficacy and tolerability over a year among patients previously treated with DMARDs and/or biologic agents" said Dr Arthur Kavanaugh, Professor of Medicine at the University of California, San Diego. "These results show that apremilast may become a potential therapy for psoriatic arthritis patients," he added.

PALACE-1 is a phase III multi-centre, double-blind, placebo-controlled, parallel-group study with two active-treatment groups. 504 patients with active psoriatic arthritis, despite prior disease-modifying anti-rheumatic drugs (DMARDs) and/or biologicals over the previous 24 weeks were randomised 1:1:1 to receive either apremilast 20 mg twice daily, 30 mg twice daily or identically-appearing placebo for 24 weeks.

The primary endpoint of the study was the proportion of patients in each treatment group who achieved ACR20 compared to baseline at week 16. Secondary endpoints included other measures of symptoms and signs, physical function and patient-reported outcomes.

At week 16, significantly more apremilast 20mg (31.3%; P=0.0140) and apremilast 30mg patients (40.0%; P<0.0001) achieved an ACR20 vs. placebo (19.4%). At week 52, by which time all patients had received a minimum of 28 weeks treatment with apremilast, response was generally maintained over the treatment period. At week 52, ACR20 was achieved by 63.0% (apremilast 20mg) and 54.6% (apremilast 30mg) of patients.

At week 16, patients in the placebo group with <20% reduction in swollen/tender joints were re-randomised to apremilast 20mg or apremilast 30mg; placebo patients with ≥20% reduction in swollen/tender joints at week 16 were re-randomised to apremilast 20mg or apremilast 30mg at week 24; patients receiving apremilast remained on their initial dose. At week 24, all remaining placebo patients were re-randomised to apremilast 20mg or apremilast 30mg through to week 52.

Exposure-adjusted incidence rates for adverse events (AEs), severe AEs, and serious AEs were comparable between 0-24 and 0-52 wks. The proportion of patients remaining on apremilast to week 52 who first reported the most common GI disturbances (e.g., diarrhoea, nausea, and vomiting) after week 24 was low (ranging from 0.6-3% for apremilast 20mg and 0-1.8% for apremilast 30mg). There were no clinically meaningful laboratory findings with exposure up to 52 weeks.

No safety signals with respect to major cardiac events, malignancies, and opportunistic infections were observed, consistent with the 0-24 week period. No cases of lymphoma, tuberculosis, or tuberculosis reactivations were reported for the 52-week period.


'/>"/>

Contact: EULAR Press Office
eularpressoffice@cohnwolfe.com
44-020-733-15364
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. No increased risk of infection for long-term sex partners of people with HPV-related oral cancers
2. Integrated stroke care system results in fewer deaths, discharges to long-term care facilities
3. Sun Damage - The Long-Term Benefits of Sunscreen
4. Long-Term Use of Antibiotic May Help Those With COPD
5. Long-term outcomes in patients with advanced coronary artery disease are better than expected
6. Erectile Dysfunction Tied to Long-Term Narcotic Use in Men
7. Long-term use of prescription painkillers for back pain linked to erectile dysfunction in men
8. BMA Affordable Assisted Living Community to Host Informational Program on Long-Term Care Insurance
9. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Unlimited Support To Dieters, Making the Transfer to Long-term Improved Health Easier
10. A "FAST" Response to Stroke Can Reduce Long-Term Damage
11. Chickenpox Shot Provides Long-Term Protection, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology: